WAYNE, Pennsylvania, Oct. 6, 2014 /PRNewswire/ -- Bracket, a leading clinical trial specialty services provider, today announced the addition of Jeffrey W. Kinell as Chief Executive Officer and as a new member of its Board of Directors.
Jeff brings more than 30 years of experience to Bracket, primarily in leadership positions in growth oriented, health services and pharmaceutical outsourcing firms. Most recently, Jeff was CEO of CRI Lifetree, a mid-size specialized research organization focused in early phase clinical development. During his five-year tenure, Jeff oversaw the firm's transformation into a scientifically driven organization offering highly specialized capabilities across multiple therapeutic areas that are in high demand by both pharmaceutical and biotech companies.
"I've been fortunate to work closely with Bracket and many of its customers over the years," said Jeff. "I've seen first-hand how this team's commitment to scientific leadership, technological innovation and operational excellence makes it one of the most exciting and innovative companies in the specialty clinical arena. I'm honored and privileged to join Bracket, and to help build an even more successful future for the organization, our clients, and for the countless individuals whose lives are improved by medications we help advance."
"Jeff intimately understands the pharma/biotech specialty clinical space and the unique demands of clinical trials in multiple therapeutic areas and across multiple study phases," said David G. Daniel, M.D., Bracket Senior Vice President and Chief Medical Director. "This, combined with his broad experience across science, technology, and operations, makes him the perfect fit for Bracket, especially as we continue to innovate and grow as an independent, privately held company."
Jim Primerano, Bracket Senior Vice President and General Manager for the eClinical group added, "Jeff's experience and leadership will be invaluable to our existing team, and I know that Bracket and our clients are going to benefit greatly from his years of providing dynamic solutions to the biopharmaceutical market. He has a true commitment to innovative products, and a unique perspective from actually dealing with the practical challenges of implementing technology solutions in a clinical environment. He sees the obvious benefits of adopting technology solutions in clinical trials to create efficiencies and improve quality."
About Bracket
Bracket partners with sponsors and contract research organizations to achieve greater certainty and accurate outcomes in their clinical trials by providing a combination of scientific, technological and operational support, from Phase I to post approval.
- Bracket's eClinical services are technology-driven solutions, applicable across a variety of therapeutic areas.
- Bracket RTSM™ technology is designed to support study design and operational effectiveness in clinical development.
- Bracket's Scientific Services target indications that are dependent on subjective endpoints (Clinical Outcome Assessments) to evaluate safety, efficacy and value, and include Endpoint Reliability, Trial Enhancement Services and Computerized Cognitive Testing.
Bracket is a member of the Electronic Patient-Reported Outcome (ePRO) Consortium, a program run by the Critical Path Institute (C-Path). The collaboration works to improve the quality of patient reported outcomes, a crucial element in the drug development process. The members of the ePRO Consortium collaborate in a non-competitive, neutral environment to develop guidelines and advance the quality of electronic data collection methods for PROs.
Bracket is a leader in the specialty services field in the U.S., U.K., Continental Europe and Japan. For more information, visit www.bracketglobal.com.
Contact:
Annette Larkin
+1-703-772-6427
larkinannette@yahoo.com
Share this article